Search trials – HealthDB

AI · alzheimer

Намерени 72 изпитвания за "alzheimer" Стр. 4 от 4

Active (not recruiting) Phase 1/2

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimers Disease

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.

Начало: 15.03.2021 Край: 30.06.2030 Възраст: 50–85 г. Treatment

Australia, Canada, Chile +6 Hoffmann-La Roche NCT04639050

Active (not recruiting) Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

Alzheimer Disease

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. Trial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up.

Начало: 19.06.2020 Край: 01.11.2028 Възраст: 60–85 г. Treatment

Australia, Canada, Czechia +6 Eli Lilly and Company NCT04437511

Active (not recruiting) Phase 3

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

Early Alzheimer's Disease

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.

Начало: 27.03.2019 Край: 30.06.2029 Възраст: 50–90 г. Treatment

Australia, Canada, China +11 Eisai Inc. NCT03887455

Active (not recruiting) Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)

Mild to moderate Alzheimer’s Disease

Trial status: Authorised Change from baseline in ADCS-ADL at Week 24, Change from baseline in NPI total score at Week 24, Occurence of AEs and SAEs, AESIs, AEs leading to study intervention discontinuation, AEs leading to study discontinuation, and AEs leading to death through Week 24, Incidence and severity of clinically significant changes in vital signs, ECG, C-SSRS, weight, and safety laboratory tests through Week 24 Change from baseline in ADAS-Cog11 at Week 24, CIBIC+ at Week 24

Начало: 21.10.2025 Възраст: от 18 г.

Croatia, Czech Republic, Germany +5 Bristol-Myers Squibb Services Unlimited Company 2025-520746-30-00

Active (not recruiting)

Internet-based Mind-Body Training for Brain Health

Subjective Cognitive Decline

The goal of this study is to conduct a Stage I pilot study examining the feasibility, acceptability, and preliminary effects of an internet-based, asynchronous mindfulness-based stress reduction program (iMBSR) compared to an internet-based, asynchronous lifestyle education program (iLifeEd), for adults at-risk for Alzheimer's disease (AD). Sixty middle-aged and older adults (aged 50 years or older) with subjective cognitive decline will be randomized to either an 8-week iMBSR program or an 8-week iLifeEd program control group, designed to provide adequate control for placebo effects. Behavioral, neuroimaging, and ecological momentary assessment (EMA) measures of mind-wandering will be administered to determine preliminary effects as a function of engagement in the iMBSR program. AD biomarkers will be examined at pre-training and post-training assessments.

Начало: 13.06.2025 Край: 01.08.2026 Възраст: от 50 г.

United States Ohio State University NCT07019402

Active (not recruiting) Phase 2

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

Alzheimer Disease

This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.

Начало: 29.07.2024 Край: 01.06.2026 Възраст: 45–85 г. Treatment

Australia Spinogenix NCT06427668

Active (not recruiting) Phase 2

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Mild Cognitive Impairment Due to Alzheimer's Disease Alzheimer's Disease Dementia

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on what dose of BIIB080 slows worsening of AD the most. To help answer this question, researchers will use the Clinical Dementia Rating-Sum of Boxes, also known as the CDR-SB. * Clinicians use the CDR-SB to measure several categories of dementia symptoms. * The results for each category are added together for a total score. Lower scores are better. Researchers will also learn more about the safety of BIIB080. The study will be split into 2 parts. The 1st part is the Placebo-Controlled Period. The 2nd part is the Long-Term Extension (LTE) Period. The 2nd part of the study will help researchers learn about the long-term safety of BIIB080, and how it affects the participant's daily life, thinking, and memory abilities in the longer term. A description of how the study will be done is given below. * After screening, participants will first receive either a low dose or high dose of BIIB080, or a placebo, as an injection into the fluid around the spinal cord (cerebrospinal fluid). A placebo looks like the study drug but contains no real medicine. * Participants will receive BIIB080 or placebo once every 12 weeks or 24 weeks. * After 76 weeks of treatment in the Placebo-Controlled Period, eligible participants will move onto the Extension Treatment period, which will last 96 weeks. * In the extension period, participants who received placebo will be switched to high dose BIIB080 every 12 or 24 weeks. * Participants may be in the study for up to 201 weeks, or about 4 years. This includes the screening and follow-up periods. * Participants can continue to take certain medications for AD. Participants must be on the same dose of medication for at least 8 weeks before the screening period. * After the screening period, most participants will visit the clinic every 6 weeks.

Начало: 24.08.2022 Край: 08.01.2029 Възраст: 50–80 г. Treatment

Australia, Belgium, Canada +12 Biogen NCT05399888

Active (not recruiting)

Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias

Alzheimer Disease Dementia Cognitive Dysfunction

Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for personalized medicine and clinical trials.

Начало: 01.07.2022 Край: 01.08.2027 Възраст: от 65 г.

Australia, United States Anne Murray NCT07224139

Active (not recruiting)

Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet in Stroke Patients Patients

Cognitive Decline Dementia, Vascular Alzheimer Disease Dementia +1

To test the effects of a 2- to 3-year intervention of the MIND diet versus usual post-stroke care on cognitive decline, the characteristic feature of dementia, and on brain biomarkers of Alzheimer's Disease (AD) and vascular disease in a Phase Ill randomized controlled trial of 250 patients hospitalized for acute ischemic stroke, aged 55 years or older, and without dementia who are discharged home following hospitalization.

Начало: 14.12.2021 Край: 31.07.2026 Възраст: от 55 г.

United States Rush University Medical Center NCT04337255

Active (not recruiting)

Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment

Mild Cognitive Impairment Memory Impairment

More than 5 million people live with Alzheimer's dementia (AD) in North America. No effective treatment exists yet probably because by the time AD has developed it is too late to intervene. Mild Cognitive Impairment (MCI) is a clinical state that typically precedes AD. In MCI, the prefrontal cortex supports compensatory mechanisms that depend on robust synaptic plasticity and that delay progression to AD. Using a neurostimulation approach that enhances prefrontal cortical plasticity in vivo, this project aims to enhance prefrontal cortical plasticity and function in patients with MCI. If successful, this project would discover a treatment modality that enhances compensation in MCI and ultimately, prevents progression to AD.

Начало: 12.10.2020 Край: 01.12.2026 Възраст: от 60 г.

Canada Centre for Addiction and Mental Health NCT04583215

By invitation only

Efficacy and Safety of Temporal Interference Stimulation on Cognitive Function in Patients With Early-Stage Alzheimer's Disease

Alzheimer Disease

This study aims to investigate the efficacy and safety of a novel non-invasive brain stimulation technique-Temporal Interference Stimulation (TIS)-in patients with early-stage Alzheimer's disease. A total of 40 participants will be randomly assigned to either the TIS group or the sham stimulation group. The intervention will last for 2 weeks, with cognitive and safety assessments at baseline, post-treatment, and 12 weeks after treatment.

Начало: 01.11.2025 Край: 30.09.2027 Възраст: 50–75 г.

China Ruijin Hospital NCT07543094

By invitation only

Probing the Role of Feature Dimension Maps in Visual Cognition: Manipulations of Relevant Locations on Salience Processing? (Expt 3.1 Pilot)

Basic Science: Visual Attention in Healthy Participants Attention

How do we know what's important to look at in the environment? Sometimes, we need to look at objects because they are 'salient' (for example, bright flashing lights of a police car, or the stripes of a venomous animal), while other times, we need to ignore irrelevant salient locations and focus only on locations we know to be 'relevant'. These behaviors are often explained by the use of 'priority maps' which index the relative importance of different locations in the visual environment based on both their salience and relevance. In this research, we aim to understand how these factors interact when determining what's important to look at. Specifically, we are evaluating the extent to which the visual system considers locations that are known to be irrelevant when considering the salience of objects. We're testing the hypothesis that the visual system always computes maps of salient locations within 'feature maps', but that activity from these maps is not read out to guide behavior for task-irrelevant locations. We'll have people look at displays containing colored shapes and/or moving dots and report aspects of the visual stimulus (e.g., orientation of a line within a particular stimulus). We'll measure response times across conditions in which we manipulate the presence/absence of salient distracting stimuli and provide various kinds of cues about the potential relevance of different locations on the screen. The rationale is that by measuring changes in visual search behavior (and thus inferring computations performed on brain representations), we will determine how these aspects of simplified visual environments impact the brain's representation of important object locations. This will support future studies using brain imaging techniques aimed at identifying the neural mechanisms supporting the extraction of salient and relevant locations from visual scenes, which can inform future diagnosis/treatment of disorders which can impact our ability to perform visual search (e.g., schizophrenia, Alzheimer's disease).

Начало: 06.02.2025 Край: 01.02.2027 Възраст: 18–55 г.

United States University of California, Santa Barbara NCT06852521

1 2 3 4